A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF 006 in Healthy Subjects (Part 1 and Part 2)
Latest Information Update: 08 May 2024
At a glance
- Drugs DF-006 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- 02 May 2024 According to a Drug Farm media release, data from this study was accepted as a late breaking poster presentation at the 2024 European Association for the Study of the Liver (EASL) conference that will be held in Milan, Italy between 05 June 2024 to 08 June 2024.
- 26 Sep 2023 According to a Drug Farm media release, the first chronic hepatitis B patient in Part 3 has been dosed.
- 16 May 2023 According to a Drug Farm media release, company has raised the first round of C series financing totaling $27 million USD. with this financing round, company will continue this clinical program on DF-006